CKD Bio Corp. (KRX:063160)

South Korea · Delayed Price · Currency is KRW

12,840

-40 (-0.31%)

At close: Sep 22, 2026

Market Cap	70.66B -47.4%
Revenue (ttm)	159.93B +3.6%
Net Income	-23.13B
EPS	-4,216.38
Shares Out	5.49M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,418
Open	12,950
Previous Close	12,880
Day's Range	12,730 - 13,040
52-Week Range	11,770 - 24,900
Beta	0.61
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About CKD Bio

CKD Bio Corp. engages in the manufacturing and sale of pharmaceutical products in South Korea, Europe, Asia, the Middle East, and internationally. The company is also involved in real estate leasing and related ancillary; bio, cosmetics, and health functional food; property management; advertising communication; consulting, construction, and maintenance of corporate IT systems business. It also exports its products. The company was founded in 1941 and is headquartered in Seoul, South Korea. [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1941

Employees 519

Stock Exchange Korea Stock Exchange

Ticker Symbol 063160

Full Company Profile

Financial Performance

In 2022, CKD Bio's revenue was 156.04 billion, an increase of 9.70% compared to the previous year's 142.24 billion. Losses were -16.70 billion, 154.0% more than in 2021.

Financial Statements